News | October 24, 2007

Carotid Artery Stenting Trials Meet AHA Guidelines

October 25, 2007 — Two carotid stenting trials examining outcomes in real-world patients demonstrated for the first time results that are comparable to guidelines established by the American Heart Association (AHA) for patients treated with carotid artery surgery, the results of which were presented by William Gray, M.D., FACC, of Columbia University Medical Center in New York at TCT 2007.

Patients treated with carotid stents in Abbott’s CAPTURE 2 (Carotid ACCULINK/ACCUNET Post Approval Trial to Uncover Rare Events) and EXACT (Emboshield and Xact Post Approval Carotid Stent Trial) post-marketing trials, which enrolled 4,111 patients, demonstrated 30 day patient outcome results that are comparable to the AHA outcome guidelines for patients less than 80 years old who undergo carotid surgery (carotid endarterectomy). These guidelines recommend stroke and death rates that are within 3 percent for patients without symptoms of stroke (asymptomatic) and 6 percent for patients with symptoms of stroke (symptomatic).

"With these two very large, well-conducted, real-world carotid artery stenting trials, not only has carotid stenting achieved a comparable outcome to guidelines established for patients who undergo carotid surgery, but it also did so in a population of patients who are at high risk for experiencing adverse events from surgery," said Dr. Gray "This is significant because this is the first time physicians have achieved results in high surgical risk candidates that are comparable to the long-standing guidelines that were established for lower surgical risk candidates, demonstrating that stenting can provide a reliable non-surgical alternative for patients facing the difficult decision of how to manage their carotid artery disease."

In 1998, the American Heart Association published its 30 day outcome guidelines in Circulation for patients treated with carotid artery surgery. These guidelines were based on the observed stroke and death rates in patients with carotid artery disease who had undergone surgery, or carotid endarterectomy, to treat their condition. The patients who underwent carotid artery surgery were at standard risk for experiencing an adverse event from surgery. Abbott's post-marketing CAPTURE 2 and EXACT studies are the first real-world carotid artery stenting studies to demonstrate results comparable to these goals.

For more information: www.abbottvascular.com


Related Content

News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
News | Cardiovascular Clinical Studies

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk ...

Home January 14, 2025
Home
News | Cardiovascular Clinical Studies

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
Subscribe Now